Monitor the company's next 10-Q filing for any updates on financial performance or guidance, as this proxy statement contains no new financial information.
PCVX drugs
PCVX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 24 $59.49entry
- T+1 · 7mo ago +0.39%α +0.22% · $59.72
- T+5 · 7mo ago −3.78%α −4.69% · $57.24
- T+20 · 6mo ago −20.34%α −24.37% · $47.39
- T+60 · 4mo ago −2.44%α −7.52% · $58.04
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vaxcyte, Inc. (PCVX) has filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting, scheduled for June 15, 2026. The meeting will vote on the election of three Class III directors, the ratification of Deloitte & Touche LLP as the independent auditor, and the approval of executive compensation. The filing is routine and does not contain any material financial data or significant corporate actions.
Key Financial Metrics
Key Facts
- The filing is a definitive proxy statement (DEFA14A) for the 2026 Annual Meeting.
- The meeting will be held on June 15, 2026.
- Proposals include the election of three Class III directors: Olivier Brandicourt, Halley Gilbert, and Grant E. Pickering.
- The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for 2026 will be ratified.
- The compensation of the named executive officers will be approved on an advisory basis.
- The Board recommends voting 'For' on all proposals.
- The filing is routine and does not contain any material financial data or significant corporate actions.
Financial Impact
No material financial impact. The filing is a routine administrative document.
Risk Factors
- The lack of new financial information or strategic updates in the filing means investors must wait for the next quarterly report for material updates.
- The advisory vote on executive compensation could be a point of contention for shareholders, although it is non-binding.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-173686 |
| Document: 0001193125-26-173686-index-headers.html | 0001193125-26-173686 |
| Document: 0001193125-26-173686-index.html | 0001193125-26-173686 |
| Document: 0001193125-26-173686.txt | 0001193125-26-173686 |
Track record
29 reports on PCVX
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +10.87% at T+5 after the Oct 8, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $62.40 Now $63.37 +1.55% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $64.69 Now $63.37 −2.04% settles Dec 11
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $63.89 Now $63.37 −0.81% settles Dec 7
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $63.89 Now $63.37 −0.81% settles Dec 7
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $61.92 Now $63.37 +2.34% settles Dec 4
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $61.92 Now $63.37 +2.34% settles Dec 4
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $60.81 Now $63.37 +4.21% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $60.81 Now $63.37 +4.21% settles Dec 2
- Oct 9, 20265w ago 8-K Bearish 6/10 Entry $70.65 to $67.53 Now $63.37 +10.30% ▲ +4.42% +1.15% vs SPY
- Oct 8, 20265w ago 424B5 Bearish 6/10 Entry $71.38 to $63.89 Now $63.37 +11.22% ▲ +10.49% +4.93% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers